House committee plans to examine FDA's drug-safety efforts

03/4/2010 | Reuters

The House Energy and Commerce Committee scheduled a hearing Wednesday to look into the FDA's drug-safety efforts amid criticism that the agency is slow to respond to reports of adverse reactions to approved treatments. Deputy FDA Commissioner Joshua Sharfstein will appear before a health subcommittee as part of the inquiry.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ